Skip to main content

Table 5 Univariate and multivariate analysis of clinicopathologic factors for OS

From: Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Variables

Univariate

Multivariate

HR

95% CI

P

HR

95% CI

P

Age (years)

 < 60 yr

1.000

  

1.000

  

 ≥ 60 yr

1.540

1.107–2.141

0.010

1.418

1.000–2.011

0.050

Sex

 Male

1.000

     

 Female

1.105

0.777–1.571

0.577

   

BMI

 < 23

1.000

     

 ≥ 23

1.020

0.735–1.417

0.905

   

Surgical approach

 Traditional open

1.000

     

 Laparoscopic-assisted

0.918

0.640–1.318

0.644

  

0.769

Intraoperative blood loss

 ≤ 100 ml

1.000

  

1.000

  

 >100 ml

1.740

1.191–2.527

0.004

1.780

1.211–2.617

0.003

Postoperative complications

 Negative

1.000

     

 Positive

1.551

1.001–2.404

0.050

  

0.729

Tumor length/diameter

 < 5 cm

1.000

     

 ≥ 5 cm

1.738

1.254–2.408

0.001

  

0.288

Histological type

 HD/MD/M-LD

1.000

     

 LD/MA/SRC

1.489

1.072–2.068

0.018

  

0.094

Vascular tumor embolus

 Negative

1.000

     

 Positive

1.956

1.372–2.789

< 0.001

  

0.626

Depth of Invasion (T)

 T1/T2/T3

1.000

     

 T4a/T4b

2.133

1.525–2.983

< 0.001

  

0.526

Lymph node metastasis (N)

 N0/N1

1.000

     

 N2/N3

3.247

2.227–4.736

< 0.001

  

0.336

TNM

  

< 0.001

  

< 0.001

 IIA

1.000

     

 IIB

2.905

1.263–6.680

0.012

2.667

1.158–6.142

0.021

 IIIA

4.375

2.067–9.259

< 0.001

4.579

2.162–9.697

< 0.001

 IIIB

8.092

3.817–17.156

< 0.001

9.092

4.277–19.327

< 0.001

 IIIC

14.987

6.776–33.145

< 0.001

16.948

7.627–37.662

< 0.001

Serum CEA level

 ≤ 5 ng/ml

1.000

     

 >5 ng/ml

1.183

0.802–1.744

0.396

   

Serum CA199 level

 ≤ 37 U/ml

1.000

     

 >37 U/ml

1.333

1.082–1.644

0.007

  

0.981

Adjuvant chemotherapy cycles

  

< 0.001

  

< 0.001

 Not received (A)

1.000

  

1.000

  

 7–8 or 10–12 cycles (B)

0.459

0.301–0.699

< 0.001

0.386

0.247–0.604

< 0.001

 4–6 or 6–9 cycles (C)

0.504

0.314–0.807

0.004

0.493

0.304–0.800

0.004

 ≤ 3 or 5 cycles (D)

1.032

0.638–1.670

0.897

0.870

0.530–1.427

0.580

  1. Note: HD/MD/M-LD High/Median/Median-Low differentiation adenocarcinoma, LD/MA/SRC Low differentiation adenocarcinoma/Mucinous adeno-carcinoma/ Signet-ring cell carcinoma, HR Hazard ratio, CI Confidence interval. P < 0.05, statistically significant